Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
Scientific presentation

Investigation of AML clonal architecture with mutational and immunophenotypic profiling simultaneously from the same cell(s)


Linde Miles, PhD
Description

Acute myeloid leukemia (AML) is a molecularly diverse hematology disease with a poor survival rate. Only 25% of patients diagnosed survive. Therefore, it is important to gain a better understanding of the disease progression by using new technologies like single-cell DNA sequencing. Leukemogenesis is thought to be a stepwise process. However, bulk sequencing only infers the order of mutation acquisition. Linde Miles, of Ross Levine’s lab at Memorial Sloan Kettering Cancer Center, shares findings from her study where she immunophenotyped and genotyped AML samples to track the order of mutations using a custom molecular panel, covering key genes for AML, MPN, and MDS. Furthermore, through a simple add-on to the workflow, she confirmed protein expression with molecular data to understand enrichment and differentiation patterns. Discover how the Tapestri Platform provides a true multi-omics approach for deeper insight into systems biology and patterns of tumor evolution, therapy response, and resistance.



VIEW


Scientific presentation
Single cell Genotypic and Immunotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia
Ross Levine, MD
Tapestri scMRD for AML Summit (2022)
Scientific presentation
Bioinformatics approach to demultiplexing scMRD
Troy Robinson, MSKCC
Tapestri scMRD for AML Summit (2022)
Scientific presentation
Opportunities for Single-cell Multi-omics in the Clinic: MRD and Beyond
Ross Levine
Marina Konopleva
Saar Gill
Wenbin Xiao
Mikhail Roshal
Tapestri scMRD for AML Summit (2022)
Scientific presentation
Single-cell Multi-omics and the Horizon of Clinical Utility
Aaron Llanso
(2022)
REQUEST QUOTE